Across TCGA pan-cancer cohorts, LINC01654 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of LINC01654’s most consistent transcriptional readouts.
The strongest signal is observed in prostate adenocarcinoma (PRAD), where LINC01654 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC01654 is over-expressed in tumor.
PRAD are the cancer types where LINC01654 tumor–normal differential expression is most reproducible.